Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chroni...(s results. There can be no assurance tha...),Health

Date:6/26/2008

s results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

References:

1. Doghramji K. Melatonin and its receptors: a new class of

sleep-promoting agents. J Clin Sleep Med. 2007;3:S17-S23.

2. Rajput V, Bromley SM. Chronic insomnia: a practical review. AAFP.

1999;60:1431-1438.

3. National Sleep Foundation. Most Common Sleep Problems in Women.

Available at:

http://www.sleepfoundation.org/site/c.huIXKjM0IxF/b.2421125/

k.6662/Most_Common_Sleep_Problems_in_Women.htm. Accessed on

June 18, 2008.

4. Centers for Disease Control and Prevention. Perceived Insufficient

Rest or Sleep - Four States, 2006. MMWR. 2008;57:200-203.

5. National Institutes of Health. NIH State-of-the-Science Conference

Statement on Manifestations and Management of Chronic Insomnia in

Adults. Available at:

SOURCE Vanda Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients